Consequently, ERK5 kinase inhibitors (such as the XMD8-92 compound) or ERK5 silencing show antiproliferative activity in different cancer cell lines and block tumor growth in animal models (human tumor xenografts). This evidence concerns the gene MAPK7 and neoplasm.